Abelson Virus Transformation Prevents TRAIL Expression by Inhibiting FoxO3a and NF-κB

Molecules and Cells

Volumn 29, Issue 4, 2010, Pages 333-342

  Wilson, Mary K ^a   McWhirter, Sarah M ^a   Amin, Rupesh H ^a   Huang, Dan ^a   Schlissel, Mark S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abelson murine leukemia virus; FoxO3a; NF kappaB; pro B cell leukemia; TRAIL

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, MOUSE; I KAPPA B KINASE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANIMAL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL LINE; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MOUSE; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS CELL TRANSFORMATION; WESTERN BLOTTING;

ABELSON MURINE LEUKEMIA VIRUS; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; G1 PHASE; HOST-PATHOGEN INTERACTIONS; I-KAPPA B KINASE; MICE; MUTATION; NF-KAPPA B; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC;

EID: 77956052321     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-010-0029-8     Document Type: Article

References (53)

1. Abelson, H.T., Rabstein, L.S., Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 30 (1970), 2213–2222.
2. Advani, A.S., Pendergast, A.M., Bcr-Abl variants: biological and clinical aspects. Leuk. Res. 26 (2002), 713–720.
3. Alt, F.W., Yancopoulos, G.D., Blackwell, T.K., Wood, C., Thomas, E., Boss, M., Coffman, R., Rosenberg, N., Tonegawa, S., Baltimore, D., Ordered rearrangement of immunoglobulin heavy chain variable region segments. Embo J. 3 (1984), 1209–1219.
4. Amin, R.H., Schlissel, M.S., Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat. Immunol. 9 (2008), 613–622.
5. Baetu, T.M., Kwon, H., Sharma, S., Grandvaux, N., Hiscott, J., Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J. Immunol. 167 (2001), 3164–3173.
6. Banerjee, A., Rothman, P., IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling. J. Immunol. 161 (1998), 4611–4617.
7. Biggs, W.H.3rd, Meisenhelder, J., Hunter, T., Cavenee, W.K., Arden, K.C., Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA 96 (1999), 7421–7426.
8. Brunet, A., Park, J., Tran, H., Hu, L.S., Hemmings, B.A., Greenberg, M.E., Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21 (2001), 952–965.
9. Chen, M., Wang, J., Initiator caspases in apoptosis signaling pathways. Apoptosis 7 (2002), 313–319.
10. Chen, Y.Y., Wang, L.C., Huang, M.S., Rosenberg, N., An active v-abl protein tyrosine kinase blocks immunoglobulin light-chain gene rearrangement. Genes Dev. 8 (1994), 688–697.
11. Cory, S., Huang, D.C., Adams, J.M., The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22 (2003), 8590–8607.
12. Deng, Y., Lin, Y., Wu, X., TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16 (2002), 33–45.
13. Derudder, E., Cadera, E.J., Vahl, J.C., Wang, J., Fox, C.J., Zha, S., van Loo, G., Pasparakis, M., Schlissel, M.S., Schmidt-Supprian, M., et al. Development of immunoglobulin lambda-chain-positive B cells, but not editing of immunoglobulin kappa-chain, depends on NF-kappaB signals. Nat. Immunol. 10 (2009), 647–654.
14. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., Lydon, N.B., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996), 561–566.
15. Fang, W., Rivard, J.J., Ganser, J.A., LeBien, T.W., Nath, K.A., Mueller, D.L., Behrens, T.W., Bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli. J. Immunol. 155 (1995), 66–75.
16. Ghaffari, S., Jagani, Z., Kitidis, C., Lodish, H.F., Khosravi-Far, R., Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc. Natl. Acad. Sci. USA 100 (2003), 6523–6528.
17. Green, P.L., Kaehler, D.A., Bennett, L.M., Risser, R., Multiple steps are required for the induction of tumors by Abelson murine leukemia virus. J. Virol. 63 (1989), 1989–1994.
18. Hacker, H., Karin, M., Regulation and function of IKK and IKK-related kinases. Sci STKE, 2006, 2006, re13.
19. Hakansson, P., Nilsson, B., Andersson, A., Lassen, C., Gullberg, U., Fioretos, T., Gene expression analysis of BCR/ ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes Chromosomes Cancer 47 (2008), 267–275.
20. Henson, E.S., Johnston, J.B., Gibson, S.B., The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk. Lymphoma 49 (2008), 27–35.
21. Hosaka, T., Biggs, W.H.3rd, Tieu, D., Boyer, A.D., Varki, N.M., Cavenee, W.K., Arden, K.C., Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl. Acad. Sci. USA 101 (2004), 2975–2980.
22. Hu, M.C., Lee, D.F., Xia, W., Golfman, L.S., Ou-Yang, F., Yang, J.Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117 (2004), 225–237.
23. Huang, H., Tindall, D.J., Dynamic FoxO transcription factors. J. Cell Sci. 120 (2007), 2479–2487.
24. Hueber, A.O., Zornig, M., Bernard, A.M., Chautan, M., Evan, G., A dominant negative Fas-associated death domain protein mutant inhibits proliferation and leads to impaired calcium mobilization in both T-cells and fibroblasts. J. Biol. Chem. 275 (2000), 10453–10462.
25. Kabra, N.H., Kang, C., Hsing, L.C., Zhang, J., Winoto, A., T cell-specific FADD-deficient mice: FADD is required for early T cell development. Proc. Natl. Acad. Sci. USA 98 (2001), 6307–6312.
26. Kawai, H., Nie, L., Yuan, Z.M., Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl. Mol. Cell. Biol. 22 (2002), 6079–6088.
27. Kikuchi, S., Nagai, T., Kunitama, M., Kirito, K., Ozawa, K., Komatsu, N., Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci. 98 (2007), 1949–1958.
28. Klug, C.A., Gerety, S.J., Shah, P.C., Chen, Y.Y., Rice, N.R., Rosenberg, N., Singh, H., The v-abl tyrosine kinase negatively regulates NF-kappa B/Rel factors and blocks kappa gene transcription in pre-B lymphocytes. Genes Dev. 8 (1994), 678–687.
29. Komatsu, N., Watanabe, T., Uchida, M., Mori, M., Kirito, K., Kikuchi, S., Liu, Q., Tauchi, T., Miyazawa, K., Endo, H., et al. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J. Biol. Chem. 278 (2003), 6411–6419.
30. Kruyt, F.A., TRAIL and cancer therapy. Cancer Lett. 263 (2008), 14–25.
31. Lee, J.Y., Huerta-Yepez, S., Vega, M., Baritaki, S., Spandidos, D.A., Bonavida, B., The NO TRAIL to YES TRAIL in cancer therapy (review). Int. J. Oncol. 31 (2007), 685–691.
32. Lewis, S., Rosenberg, N., Alt, F., Baltimore, D., Continuing kappa-gene rearrangement in a cell line transformed by Abelson murine leukemia virus. Cell 30 (1982), 807–816.
33. Marshall, A.J., Fleming, H.E., Wu, G.E., Paige, C.J., Modulation of the IL-7 dose-response threshold during pro-B cell differentiation is dependent on pre-B cell receptor expression. J. Immunol. 161 (1998), 6038–6045.
34. Mattioni, T., Louvion, J.F., Picard, D., Regulation of protein activities by fusion to steroid binding domains. Methods Cell Biol. 43 Pt A (1994), 335–352.
35. Mauro, M.J., Druker, B.J., STI571: targeting BCR-ABL as therapy for CML. Oncologist 6 (2001), 233–238.
36. Modur, V., Nagarajan, R., Evers, B.M., Milbrandt, J., FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277 (2002), 47928–47937.
37. Muljo, S.A., Schlissel, M.S., A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines. Nat. Immunol. 4 (2003), 31–37.
38. Newton, K., Harris, A.W., Bath, M.L., Smith, K.G., Strasser, A., A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. Embo J. 17 (1998), 706–718.
39. Park, S.M., Schickel, R., Peter, M.E., Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr. Opin. Cell Biol. 17 (2005), 610–616.
40. Perkins, N.D., Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8 (2007), 49–62.
41. Ramaswamy, S., Nakamura, N., Sansal, I., Bergeron, L., Sellers, W.R., A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2 (2002), 81–91.
42. Roth, W., Reed, J.C., Apoptosis and cancer: when BAX is TRAILing away. Nat. Med. 8 (2002), 216–218.
43. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., Peter, M.E., Two CD95 (APO-1/Fas) signaling pathways. Embo J. 17 (1998), 1675–1687.
44. Schaefer, U., Voloshanenko, O., Willen, D., Walczak, H., TRAIL: a multifunctional cytokine. Front Biosci. 12 (2007), 3813–3824.
45. Sen, R., Baltimore, D., Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47 (1986), 921–928.
46. Sheehy, A.M., Schlissel, M.S., Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line. J. Biol. Chem. 274 (1999), 8708–8716.
47. Sheridan, J.P., Marsters, S.A., Pitti, R.M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C.L., Baker, K., Wood, W.I., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997), 818–821.
48. Xu, G., Shi, Y., Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res. 17 (2007), 759–771.
49. Zhang, L., Fang, B., Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12 (2005), 228–237.
50. Zhang, J., Winoto, A., A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol. Cell. Biol. 16 (1996), 2756–2763.
51. Zhang, J., Cado, D., Chen, A., Kabra, N.H., Winoto, A., Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392 (1998), 296–300.
52. Zhang, J., Kabra, N.H., Cado, D., Kang, C., Winoto, A., FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery. J. Biol. Chem. 276 (2001), 29815–29818.
53. Zou, X., Calame, K., Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J. Biol. Chem. 274 (1999), 18141–18144.